Journey Medical Corp (DERM) is not a strong buy for a beginner investor with a long-term strategy. The stock shows mixed signals with no significant positive catalysts or trading signals. The company's financial performance is weak with declining net income and EPS, despite revenue growth. Technical indicators are moderately positive, but the lack of strong trading trends, news catalysts, or analyst ratings makes this stock a hold rather than a buy.

Technical Analysis

The MACD is positive and expanding, indicating a bullish momentum. RSI is neutral at 72.848, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are Pivot: 8.33, R1: 8.899, S1: 7.761, R2: 9.251, S2: 7.409. Overall, the technical indicators suggest moderate bullishness.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Technical indicators show moderate bullish momentum.

Neutral/Negative Catalysts

Net income dropped by -3.14% YoY, EPS fell by -25.00% YoY, and gross margin declined by -3.99% YoY. No recent news, trading trends, or significant activity from insiders, hedge funds, or Congress. No AI Stock Picker or SwingMax signals.

Financial Performance

In Q3 2025, revenue increased to $17.63M (up 20.52% YoY), but net income dropped to -$2.32M (-3.14% YoY). EPS declined to -0.09 (-25.00% YoY), and gross margin decreased to 61.32% (-3.99% YoY).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

3 Analyst Rating

Wall Street analysts forecast DERM stock price to rise

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 8.170

Low

Averages

High

Current: 8.170

Low

Averages

High

Alliance Global

Buy

maintain

$10 -> $16

AI Analysis

2025-11-13

Reason

Alliance Global

Price Target

$10 -> $16

AI Analysis

2025-11-13

maintain

Buy

Reason

Alliance Global raised the firm's price target on Journey Medical to $16 from $10 and keeps a Buy rating on the shares post the Q3 report. The firm cites enthusiasm in the Emrosi launch for the target boost. It increased its peak revenue forecast to $250M from $200M for the drug.

H.C. Wainwright

Brandon Folkes

Buy

initiated

$13

2025-08-25

Reason

H.C. Wainwright

Brandon Folkes

Price Target

$13

2025-08-25

initiated

Buy

Reason

H.C. Wainwright analyst Brandon Folkes initiated coverage of Journey Medical with a Buy rating and $13 price target. The firm believes the company's Emrosi has demonstrated clinical superiority to market leader Oracea in rosacea. This creates the potential for prescription demand and revenue pull through to exceed current consensus expectations, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DERM

Unlock Now

DERM Should I Buy

DERM Should I Buy

Should You Buy Journey Medical Corp (DERM) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch